CellResearch Corporation Pte Ltd. is a pioneering life sciences company based in Singapore, established in 2002. Its primary industry focus is Biotechnology and Stem Cell Technology, with its core principal activity being research and experimental development on medical science. The company gained international prominence for its groundbreaking work in isolating and patenting stem cells derived from the umbilical cord lining membrane. This discovery positions the cord lining as a particularly rich source of both epithelial and mesenchymal stem cells, with potential yields far exceeding those from sources like bone marrow.
The company's foundational work originally involved providing specialized skin cell, scar, and keloid cell samples to research laboratories globally. This initial activity evolved following the critical discovery in 2004 of the two unique stem cell populations???epithelial and mesenchymal???within the umbilical cord lining membrane. This discovery is protected by an extensive intellectual property portfolio, currently encompassing a significant number of patents granted across multiple strategic territories worldwide.
The overriding mission of CellResearch Corporation is to exploit the therapeutic potential of these cord lining stem cells, primarily focusing on regenerative medicine and developing treatments for conditions with high unmet medical needs.
Products and Services
CellResearch Corporation's offerings are structured across several key business units, leveraging their proprietary stem cell technology across therapeutic, consumer health, and cord banking sectors.
I. Therapeutics and Research & Development
The company's most significant long-term endeavor is in the field of regenerative medicine and therapeutics. Its research pipeline focuses on developing cellular therapies derived from the cord lining stem cells.
CorLiCyte: This is the name given to the company's Current Good Manufacturing Practice (cGMP) grade cord lining mesenchymal stem cells, which are being developed for human transplantation.
Wound Healing: A major area of clinical focus involves accelerating wound healing, particularly for chronic, hard-to-heal wounds such as diabetic foot ulcers. The company has initiated USFDA clinical trials in collaboration with international partners to advance these treatments.
Therapeutic Pipeline: Beyond wound care, the company is actively engaged in research and development for other critical medical applications, including:
Burns and Wounds & Resurfacing
Age-related Macular Degeneration
Bones and Cartilage disorders
Corneal Resurfacing
Diabetes
Heart Disease
Neurological conditions, including Parkinson's disease
Lupus and Haemophilia A
Contract Research: Historically, the company has provided contract research services and supplied one of the world's largest private libraries of skin, scar, and keloid cells to research institutions like Harvard University and major corporations.
II. Cord Banking and Registry Services (CordLabs)
Through its subsidiary CordLabs, the corporation is involved in the preservation and management of cord tissue for future therapeutic use, licensing its proprietary technology globally.
Umbilical Cord Lining Stem Cell Banking: The company licenses its proprietary technology for the storage of the umbilical cord lining membrane to licensed cord blood banks across the world. This ensures that the tissue banking process is optimized to allow for the maximum outgrowth and robustness of the cord lining stem cells for future clinical application.
Global Cord Registry (GCR): CordLabs owns and manages the GCR. This registry functions as a quality assurance mechanism, ensuring that all registered banked cord lining tissues have been processed by licensed providers using the company's proprietary and validated protocols. The GCR provides a guarantee to both physicians and patients regarding the quality and viability of the banked stem cells for potential future therapy.
III. Consumer Health (CALECIMŽ Cosmeceuticals)
A commercial application of the company's stem cell research has led to the development of a professional cosmeceutical line.
CALECIMŽ: Marketed under its subsidiary CALECIM Cosmeceuticals Pte Ltd, this product line is based on a proprietary blend of secreted cell proteins derived from the red deer umbilical cord lining. The products are designed to improve the appearance of skin following topical application. This represents an important commercial bridge between the company's deep scientific expertise and the consumer health market.
The company operates with a strategy that segments its business into distinct, related entities, such as CellResearch Therapeutics Pte Ltd., CellResearch Consumer Health Pte Ltd. (formerly CALECIM Cosmeceuticals Pte. Ltd.), and CordLabs Pte Ltd., all managed under the umbrella of CellResearch Corporation Pte Ltd.
NOTE: The above writeup is a detailed, grounded description of the activities, products, and services of CellResearch Corporation Pte Ltd., a Singapore-based biotechnology company. It is based on publicly available information regarding their stem cell research, therapeutic developments, cord banking services, and cosmeceutical products.
Please note: This information is generated by AI. For legal use, verify with company sources.
